Navigation Links
Myriad Genetics Presents Mathematical Comparison of Disease,Modification Trial Designs at Alzheimer's ConferenceCurrent,Flurizan Phase 3 Study Design May Demonstrate Disease Modification

ion label for Flurizan."

About Flurizan(TM)

Myriad has two Phase 3 trials of Flurizan ongoing in patients with mild Alzheimer's disease. In each study, participants are taking 800 mg of Flurizan or placebo twice daily, and participants enrolled will have taken the study drug for 18 months. Flurizan is the first in a new class of drug candidates known as Selective Amyloid beta-42 Lowering Agents (SALAs). Flurizan lowered levels of Abeta42 in cellular assays and animal models. Abeta42 is the primary constituent of senile plaque that accumulates in the brain of patients with Alzheimer's disease. It is thought to be the key initiator of Alzheimer's disease, since Abeta42 has the greatest tendency to aggregate, cause neuronal damage and initiate amyloid deposits in the brain. Most genetic mutations that cause early-onset Alzheimer's disease appear to do so by increasing production of Abeta42. Myriad believes that Flurizan is the most advanced drug candidate that modifies the production of Abeta42 to be evaluated in a clinical trial for the treatment of Alzheimer's disease.

About Myriad

Myriad Genetics, Inc. is a biopharmaceutical company focused on the development and marketing of novel healthcare products. The Company develops and markets molecular diagnostic products, and is developing and intends to market therapeutic products. Myriad's news and other information are available on the Company's Web site at www.myriad.com. Flurizan is a trademark of Myriad Genetics, Inc. in the United States and other countries.

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include whether the Flurizan Phase 3 study design may demonstrate disease modification; the Company's use of the Natural History Staggered Start trial design and trial analysis methodology in its Flurizan Phase
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Myriad Genetics Presents Tumor Origin Technology at AACR
2. Myriad Genetics Presents Azixas Mode of Action at AACR
3. Response Genetics Announces Publication of a Phase III Clinical Trial Demonstrating That Low Levels of ERCC-1 Help to Predict Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer
4. Genetics Journal Thimerosal/Autism Study the Best Science Drug Company Money Can Buy
5. Targeted Genetics Reports Inflammatory Arthritis Clinical Data at European Rheumatology Conference
6. ZymoGenetics Reports Results From Atacicept Phase 1b Clinical Trial in B-Cell Chronic Lymphocytic Leukemia
7. Seattle Genetics Highlights Data on its Proprietary Antibody-Drug Conjugate Technology at AACR
8. Aeolus Pharmaceuticals AEOL 10150 Highlighted in Nature Genetics Publication
9. Expression Genetics, Inc. Announces Successful Completion of Phase I Trial of Gene-Based IL-12 for Treatment of Ovarian Cancer
10. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
11. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
Post Your Comments:
(Date:10/20/2014)... Mary,s Medicinals today announced that its 501(c)(3) foundation, ... Operation Grow4Vets , a national, nonpartisan organization focused ... to assist them in living with injuries sustained while ... , An ever-increasing number of medical studies have shown ... pain, Post-traumatic Stress Disorder (PTSD) and Traumatic Brain Injury ...
(Date:10/19/2014)... Oct. 20, 2014 CTI BioPharma Corp. (CTI) ... report its third quarter 2014 financial results on Wednesday, ... financial markets. Following the announcement, members of the management ... the results and provide a general corporate update at ... event can be obtained as follows: Wednesday, ...
(Date:10/17/2014)... , Oct. 17, 2014 With ... Medical Affairs function has come across several challenges ... efficiently and managing globalization.  The ... LLC is dedicated to providing benchmarking and best ... Affairs Consortium is a service composed of three ...
Breaking Medicine Technology:Mary's Medicinals Announces 4-Star Sponsorship of Operation Grow4Vets 2Mary's Medicinals Announces 4-Star Sponsorship of Operation Grow4Vets 3CTI BioPharma to Report Third Quarter 2014 Financial Results on October 29, 2014 2Early Key Findings from the Medical Affairs Consortium Research 2
... (San Jose, California), a medical device company that is pioneering ... treat the sacroiliac (SI) joint announced today that Ralph F. ... Board (MAB). Dr. Rashbaum joins noted spine surgeons Steve Garfin, ... founder, Mark Reiley, on the SI-BONE MAB. "The ...
... N.J., Dec. 6, 2010 Neurologix, Inc. (OTC Bulletin ... innovative gene therapies for disorders of the brain and ... additional financing from three of its largest existing investors, ... Palisade Capital Management, LLC. These investors have provided a ...
Cached Medicine Technology:SI-BONE Adds Texas Back Institute Founder to Its Medical Advisory Board 2SI-BONE Adds Texas Back Institute Founder to Its Medical Advisory Board 3SI-BONE Adds Texas Back Institute Founder to Its Medical Advisory Board 4Neurologix Completes Additional $7 Million Financing 2Neurologix Completes Additional $7 Million Financing 3Neurologix Completes Additional $7 Million Financing 4
(Date:10/20/2014)... Women’s health specialist, Dr. Amber Murphy, MD, ... Columbus, Inc., A Division of MaternOhio Clinical Associates, Inc., ... 100,000 patients annually. Dr. Murphy will provide a full ... a women’s life. She is accepting new patients at ... Dublin. , Dr. Murphy offers a wide variety of ...
(Date:10/20/2014)... 2014 Zereana Jess-Huff, a 34-year-old mother, corporate ... on a platform to think outside the bra. She doesn’t ... position to raise awareness about women’s other lady parts. , ... You say the color pink and everybody knows what you’re ... fact that it has not been won when it comes ...
(Date:10/20/2014)... Ohio (PRWEB) October 20, 2014 Principle ... years, takes pride in manufacturing top-of-the-line absorbent products. ... image of its most popular brand, Tranquility® Premium Protection ... created a new website, gave its packaging a new ... bring the brand message to the public. , The ...
(Date:10/20/2014)... Rockynol Retirement Community broke ground ... The $11 million project will include the latest in ... with full-service restaurant style dining. , “We are excited ... Assisted Living apartments,” said Kara Hanzie, Rockynol Executive Director ... of care and this investment is proof of our ...
(Date:10/20/2014)... 20, 2014 National Teen Driver Safety Week ... American Academy of Pediatrics (Ohio AAP, http://www.ohioaap.org ) is ... parents of teen drivers to talk to their teens and ... Motor vehicle crashes are the leading cause of death for ... in fatal crashes, and 859 (42%) of those teen drivers ...
Breaking Medicine News(10 mins):Health News:OhioHealth Welcomes New Women’s Health Specialist to MaternOhio Specialists in Obstetrics & Gynecology of Columbus, Inc. 2Health News:OhioHealth Welcomes New Women’s Health Specialist to MaternOhio Specialists in Obstetrics & Gynecology of Columbus, Inc. 3Health News:Ovarian Cancer Survivor Mrs. Maryland Urges Media to Think Outside the Bra 2Health News:Ovarian Cancer Survivor Mrs. Maryland Urges Media to Think Outside the Bra 3Health News:Tranquility® Premium Protection Incontinence Products Releases New Logo and Website 2Health News:Rockynol Retirement Community Expands Assisted Living Center 2Health News:Ohio AAP Promotes National Teen Driver Safety Week 2
... Rapi d Fire Marketing ... the medical cannabis industry. With the passing of Proposition 215, ... Fire Marketing has entered the business of providing full service ... includes medical doctors and cannabis dispensaries. , , ...
... , LANHAM, Md., Aug. 19 ... immunization awareness campaign, Protecting our Future: The COSHAR Foundation ... new materials, including updated information about autism and vaccines and ... now. , , Through this ...
... , , WOODCLIFF LAKE, N.J., ... a wholly owned subsidiary of Par Pharmaceutical Companies, Inc. (NYSE: ... and Drug Administration (FDA) has accepted the new drug application ... oropharyngeal candidiasis (OPC). Miconazole MBT delivers the antifungal miconazole ...
... SHENZHEN, China, Aug. 19 /PRNewswire-Asia-FirstCall/ -- Mindray Medical,International Limited ... and,marketer of medical devices worldwide, announced today that Mindray ... EDT at the Morgan Stanley,Global Healthcare Unplugged Conference in ... Grand Hyatt. , The conference ...
... software company to team up with healthcare, ... - rL Solutions, the leading provider of healthcare quality and ... Corporate Alliance Sponsor of the Society for Healthcare Consumer Advocacy ... the partnership, rL Solutions will randomly award 20 licenses to ...
... , , , , ... Innovations has been awarded a contract to supply hearing aids to the ... data from the Hearing Industry Association, the VA represents approximately 18 percent ... than 29 percent for the three months ended June 30, 2009 compared ...
Cached Medicine News:Health News:Rapid Fire Marketing Enters Medical Cannabis Business 2Health News:Rapid Fire Marketing Enters Medical Cannabis Business 3Health News:COSHAR Foundation Enhances National Childhood Immunization Awareness Campaign 2Health News:FDA Accepts Drug Application for Miconazole Lauriad(R) to Treat Oropharyngeal Candidiasis 2Health News:FDA Accepts Drug Application for Miconazole Lauriad(R) to Treat Oropharyngeal Candidiasis 3Health News:Mindray Medical to Present at the Morgan Stanley Global Healthcare Unplugged Conference 2Health News:rL Solutions to Become the Founding Corporate Alliance Sponsor of the Society for Healthcare Consumer Advocacy 2Health News:Sonic Innovations Awarded Contract From U.S. Veterans Administration 2Health News:Sonic Innovations Awarded Contract From U.S. Veterans Administration 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: